Health Economics

Estimated savings UK: £1.1 billion annually

Estimated savings EU: €9.8 billion annually

Guest et al. (2015, 2017) estimated the burden of wound care in the UK. They found that 2.2 million wounds annually required extended treatment and that the direct costs of these wounds were £5.3 billion. Extending these data to the EU would correspond to 17 million wounds annually resulting in direct costs of €47 million.

Two approaches were taken to evaluate the potential cost savings that can be achieved by the use of Acapsil compared to standard of care.

  1. Based on the publications by Guest et al. and data obtained on reductions in hospitalisation days and time to wound closure by Acapsil in the comparative clinical study, potential cost savings could be estimated.
  2. Costs of standard-of-care versus costs of Acapsil were determined for a number of individual wounds. There will be a high degree of variability in these data, but they will be able to confirm whether the savings estimated by the large-scale approach are realistic.

Using these approaches it was found:

  • The population approach estimated annual savings of 21%.
    This would correspond to £1.1 billion annually in savings.
  • The case report approach estimated an average saving of 66%.
    This included hospital inpatients, out-patients and community care and the level of savings were quite similar for each of the three groups.

Furthermore, in the two cases (diabetic foot ulcer and venous leg ulcer) where the patients had strong wound-associated pain, Acapsil was able to remove the pain rapidly and it did not return. In one case the patient was close to dying from a wound infection causing sepsis, but Acapsil managed to reverse this process. Acapsil also progressed a 5-year-old diabetic foot ulcer towards healing. Acapsil, consequently, offers solutions to medical problems that until now were untreatable (therapeutic advances). In order to estimate savings on these outcomes, a tentative value needs to be assigned to these, e.g. value of a life, value of living without pain and value of walking again. This latter could perhaps be calculated as opposed to the cost of a lower leg amputation but this does not take into account the higher quality of life of the patient with his/her own leg as opposed to prosthesis. Also, the calculations do not include the socio-economic benefits of the fast healing which in many cases will allow patients to keep their job and support their families or, depending on age, to continue living independently.

Finally, by using Acapsil early in the healing process it should be possible to substantially reduce the number of wounds that become chronic and this will reduce costs further.

Sources:

Guest et al. (2015, 2017).

Bilyayeva et al. (2017).